Why Ericsson Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Ericsson shares surged 10.9% premarket after beating Q3 earnings and sales estimates; other small-cap stocks saw sharp gains and losses.
Stocks · News reference
Chardan Capital Initiates Coverage On Rani Therapeutics Hldgs with Buy Rating, Announces Price Target of $6
Chardan Capital analyst Andreas Argyrides initiates coverage on Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy rating and announces Price Target of $6.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Rani Therapeutics Joins FDA Emerging Technology Platform
Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the RaniPill® Capsule™ platform technology has been accepted into the
HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and maintains $11 price target.
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top analysts changed outlook on top names. See analyst ratings page for all changes.